Locally Advanced Or Metastatic Nsclc clinical trials

Explore recruiting locally advanced or metastatic nsclc clinical trials.

Recruiting locally advanced or metastatic nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Locally Advanced Or Metastatic Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib 2024-512581-34-00

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

Netherlands, Hungary, Germany, Belgium, France, Spain +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations

Italy, Spain, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Spain, Austria, Sweden, Poland, Italy, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Greece, France, Spain, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Locally Advanced Or Metastatic Nsclc trials by city

Locally Advanced Or Metastatic Nsclc in Toronto Locally Advanced Or Metastatic Nsclc in Vancouver Locally Advanced Or Metastatic Nsclc in Montreal Locally Advanced Or Metastatic Nsclc in Calgary Locally Advanced Or Metastatic Nsclc in Edmonton Locally Advanced Or Metastatic Nsclc in Ottawa Locally Advanced Or Metastatic Nsclc in Winnipeg Locally Advanced Or Metastatic Nsclc in Quebec City Locally Advanced Or Metastatic Nsclc in Hamilton Locally Advanced Or Metastatic Nsclc in Kitchener Locally Advanced Or Metastatic Nsclc in London Locally Advanced Or Metastatic Nsclc in Halifax Locally Advanced Or Metastatic Nsclc in New York Locally Advanced Or Metastatic Nsclc in Los Angeles Locally Advanced Or Metastatic Nsclc in Chicago Locally Advanced Or Metastatic Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease